Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.41 | 5e-09 |
mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.22 | 6e-08 |
mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.32 | 7e-08 |
mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.19 | 2e-07 |
mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.28 | 8e-07 |
mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.28 | 1e-06 |
mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-06 |
mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-06 |
mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.32 | 2e-06 |